Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 15;155(8):1455-1465.
doi: 10.1002/ijc.35060. Epub 2024 Jun 24.

Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study

Manja Bloem  1   2   3 , Olivier J van Not  1   4 , Maureen J B Aarts  5 , Franchette W P J van den Berkmortel  6 , Christian U Blank  7 , Willeke A M Blokx  8 , Marye J Boers-Sonderen  9 , Johannes J Bonenkamp  10 , Jan-Willem B de Groot  11 , John B Haanen  7 , Geke A P Hospers  12 , Ellen W Kapiteijn  13 , Melissa M de Meza  1   2   3 , Djura Piersma  14 , Rozemarijn S van Rijn  15 , Marion A M Stevense-den Boer  16 , Astrid A M van der Veldt  17   18 , Gerard Vreugdenhil  19 , Alfons J M van den Eertwegh  20 , Karijn P M Suijkerbuijk  4 , Michel W J M Wouters  1   2   3
Affiliations

Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study

Manja Bloem et al. Int J Cancer. .

Abstract

Previous studies demonstrated limited efficacy of immune checkpoint inhibitors in unresectable acral melanoma (AM); it remains unclear how this translates to the adjuvant setting. This study investigates clinical outcomes of acral compared to cutaneous melanoma (CM) patients treated with adjuvant anti-PD-1 after complete resection. All stages III-IV AM and CM patients receiving adjuvant anti-PD-1 after complete resection between 2018 and 2022 were included from the prospective nationwide Dutch Melanoma Treatment Registry. We analyzed recurrence-free survival (RFS), distant metastasis-free survival (DMFS), and overall survival (OS). A multivariable Cox regression analysis of RFS was performed to adjust for potential confounders. We included 1958 (86 AM and 1872 CM) patients. At baseline, AM patients more frequently had KIT mutations, higher disease stages, and Eastern Cooperative Oncology Group Performance Status, and fewer BRAF and NRAS mutations. Median RFS was 14.8 months (95% confidence interval [CI]: 11.5-29.3) in AM and 37.4 months (95% CI: 34.6 to not reached) in CM (p = .002). After correcting for potential confounders, AM remained associated with a higher risk of recurrence (HRadj 1.53; 95% CI: 1.07-2.17; p = .019). Two-year DMFS tended to be worse for AM than for CM: 64.5% versus 79.7% (p = .050). Two-year OS was significantly lower in AM (71.5% vs. 84.3%; p = .027). The results of this study suggest a poorer outcome of adjuvant-treated AM compared to CM. Studies assessing the added value of adjuvant treatment in AM are needed. Future research should investigate alternative treatment strategies to improve outcomes of high-risk AM.

Keywords: acral melanoma; adjuvant; immune checkpoint inhibitors; immunotherapy; melanoma.

PubMed Disclaimer

References

REFERENCES

    1. van Zeijl MCT, de Wreede LC, van den Eertwegh AJM, et al. Survival outcomes of patients with advanced melanoma from 2013 to 2017: results of a nationwide population‐based registry. Eur J Cancer. 2021;144:242‐251. doi:10.1016/j.ejca.2020.11.028
    1. Ugurel S, Röhmel J, Ascierto PA, et al. Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition—update 2019. Eur J Cancer. 2020;130:130‐138. doi:10.1016/j.ejca.2020.02.021
    1. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. New Engl J Med. 2018;378(19):1789‐1801. doi:10.1056/nejmoa1802357
    1. Eggermont AMM, Chiarion‐Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high‐risk stage III melanoma (EORTC 18071): a randomised, double‐blind, phase 3 trial. Lancet Oncol. 2015;16(5):522‐530. doi:10.1016/S1470‐2045(15)70122‐1
    1. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. New Engl J Med. 2017;377(19):1824‐1835. doi:10.1056/nejmoa1709030

MeSH terms

Substances